
Neurologist

No OPD information available
Transient Ischemic Attack (TIA)
Stroke
Hypertension
Hypothermia
Pneumonia
Thrombectomy
Benjamin B. Clissold is a male healthcare provider who helps patients with various health issues such as Transient Ischemic Attack (TIA), Stroke, Hypertension, Hypothermia, Pneumonia, and Thrombectomy.
Benjamin B. Clissold works with patients to treat conditions like TIA, Stroke, and Hypertension. He uses special skills and treatments to help patients recover and improve their health. His goal is to provide the best care possible to help patients feel better.
Benjamin B. Clissold communicates with patients in a kind and caring way. Patients trust him because he listens to their concerns and explains things in a way they can understand. He shows empathy and compassion towards his patients, making them feel comfortable and supported.
To stay updated with the latest medical knowledge and research, Benjamin B. Clissold regularly attends training sessions, reads medical journals, and participates in conferences. This helps him provide the most current and effective treatments to his patients.
Benjamin B. Clissold works closely with colleagues and other medical professionals to ensure the best care for patients. He values teamwork and collaboration to achieve positive outcomes for patients. His respectful and cooperative approach makes him a trusted member of the healthcare team.
Through his work, Benjamin B. Clissold has positively impacted many patients' lives by helping them recover from serious health conditions. His dedication to providing high-quality care has led to improved health outcomes and better quality of life for his patients.
In his notable publication, "Prevalence of primary aldosteronism in acute stroke or transient ischemic attack," Benjamin B. Clissold contributes valuable research to the medical field. His clinical trial, "STOP-MSU," aims to improve treatments for intracerebral hemorrhage, showing his commitment to advancing medical knowledge and improving patient care.
Enrollment Status: Completed
Published: September 28, 2023
Intervention Type: Drug
Study Drug: Tranexamic Acid
Study Phase: Phase 2
